Lactobacillus reuteri CR20

Phase 2Biologic

UUniversidad Complutense de Madrid

Lactobacillus reuteri CR20 is one of 43 biologic programs targeting Mastitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MastitisActive, not recruiting

InfertilityActive, not recruiting

MastitisPhase 1/Phase 2

Active, not recruiting

InfertilityPhase 2

Active, not recruiting

Competition

Competitive Landscape

121 competitors in Infertility

#DrugCompanyPhaseTrials

Voltaren

Novartis

Phase 3

1 2

Victoza

Novo Nordisk

Phase 3

1 3

Depo-Provera

Activella

Zoladex

Gonal-F

3 7

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Prograf

VVeloxis Pharmaceuticals

Phase 3

1 9

Human Chorionic Gonadotropin

Merck & Co.

Phase 3

2 10

Estradiol Valerate

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mastitis2 trials

Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis

Completed·UUniversidad Complutense de Madrid·Phase 2/3·NCT00716183·300 enrolled

Study of a Probiotic Strain to Prevent Mastitis and to Eradicate GBS Colonization

Unknown status·UUniversidad Complutense de Madrid·Phase 1/2·NCT01505361·100 enrolled

Women1 trial

Global Effects of a Probiotic Strain on Lactating Women

Completed·UUniversidad Complutense de Madrid·N/A·NCT01124448·40 enrolled

Infertility1 trial

Application of Lactobacillus Salivarius CECT5713 in Infertility of Unknown Origin

Completed·UUniversidad Complutense de Madrid·Phase 2·NCT04446572·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Lactobacillus reuteri CR20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactobacillus reuteri CR20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactobacillus reuteri CR20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Complutense de Madrid company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversidad Complutense de Madrid

Lactobacillus reuteri CR20

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mastitis2 trials

Women1 trial

Infertility1 trial

References

Drug Info

Quick Facts

Related News